These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38182029)

  • 1. Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections.
    Israilevich RN; Mansour H; Patel SN; Garg SJ; Klufas MA; Yonekawa Y; Regillo CD; Hsu J
    Ophthalmology; 2024 Jun; 131(6):667-673. PubMed ID: 38182029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
    Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
    Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.
    Stem MS; Rao P; Lee IJ; Woodward MA; Faia LJ; Wolfe JD; Capone A; Covert D; Dass AB; Drenser KA; Garretson BR; Hassan TS; Margherio A; Oh KT; Raephaelian PV; Randhawa S; Sneed S; Trese MT; Yedavally S; Williams GA; Ruby AJ
    Ophthalmol Retina; 2019 Jan; 3(1):3-7. PubMed ID: 30929813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
    Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
    Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
    Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
    Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.
    Baudin F; Benzenine E; Mariet AS; Bron AM; Daien V; Korobelnik JF; Quantin C; Creuzot-Garcher C
    JAMA Ophthalmol; 2018 Dec; 136(12):1352-1358. PubMed ID: 30242325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [No Abstract]   [Full Text] [Related]  

  • 14. The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.
    VanderBeek BL; Bonaffini SG; Ma L
    Ophthalmology; 2015 Nov; 122(11):2311-2315.e1. PubMed ID: 26281823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina.
    Terzić S; Pilavdžić A; Nadarević Vodenčarević A
    Med Glas (Zenica); 2015 Aug; 12(2):202-5. PubMed ID: 26276660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
    Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
    Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
    Casparis H; Wolfensberger TJ; Becker M; Eich G; Graf N; Ambresin A; Mantel I; Michels S
    Retina; 2014 Jan; 34(1):12-7. PubMed ID: 23945639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.